• HTS-PTT 'effective and low-cost means' of BRCA mutation quantitative analysis
    Quantitative analysis of BRCA gene mutations with HTS-PTT is said to be low-cost and effective

Electrophoretic Separations

HTS-PTT 'effective and low-cost means' of BRCA mutation quantitative analysis

Oct 05 2010

Quantitative analysis of mutations in the BRCA1 and BRCA2 genes using high throughput solid-phase protein truncation testing (HTS-PTT) is a low-cost and effective way of detecting abnormalities associated with breast cancer, according to researchers.

The open-access research journal Breast Cancer Research carries the findings of the team from AmberGen, First Light Biosciences, the University of Toronto Centre for Research in Women's Health and Boston University's Molecular Biophysics Laboratory.

In previous research, the team had proposed a HTS-PTT approach to quantitative analysis of BRCA gene mutations using an enzyme-linked immunosorbent assay (ELISA).

The ELISA approach holds benefits including removing the need for subjective interpretation of the outcomes and eliminating radioactivity from the process.

In their latest testing, they discovered 96 per cent specificity in truncating mutations using their new procedure and 100 per cent diagnostic sensitivity.

They write: "Overall, the HTS-PTT provides a simple, quantitative, objective, low-cost and high-throughput method for analysis of truncating mutations."

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Lab Asia 2023

Oct 10 2023 Hybrid event

MicroTAS 2023

Oct 15 2023 Katowice, Poland

ISPPP 2023

Nov 05 2023 Vienna, Austria

SETAC North America

Nov 12 2023 Louisville, KY, USA

Eastern Analytical Symposium

Nov 13 2023 Plainsboro, NJ, USA

View all events